Study identifier:D9960C00001
ClinicalTrials.gov identifier:NCT06542250
EudraCT identifier:N/A
CTIS identifier:2024-511099-34-00
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)
B-cell Malignancies
Phase 1/2
No
AZD5492
All
174
Interventional
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Module 1: AZD5492 Monotherapy AZD5492 monotherapy for Relapsed or Refractory B-Cell Malignancies. | Drug: AZD5492 CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously |